OBJECTIVES: Large biobanks with uniform collection of biomaterials and associated clinical data are essential for translational research. The Netherlands has traditionally been well organized in multicenter clinical research on pancreatic diseases, including the nationwide multidisciplinary Dutch Pancreatic Cancer Group and Dutch Pancreatitis Study Group. To enable high-quality translational research on pancreatic and periampullary diseases, these groups established the Dutch Pancreas Biobank. METHODS: The Dutch Pancreas Biobank is part of the Parelsnoer Institute and involves all 8 Dutch university medical centers and 5 nonacademic hospitals. Adult patients undergoing pancreatic surgery (all indications) are eligible for inclusion. Preoperative blood samples, tumor tissue from resected specimens, pancreatic cyst fluid, and follow-up blood samples are collected. Clinical parameters are collected in conjunction with the mandatory Dutch Pancreatic Cancer Audit. RESULTS: Between January 2015 and May 2017, 488 patients were included in the first 5 participating centers: 4 university medical centers and 1 nonacademic hospital. Over 2500 samples were collected: 1308 preoperative blood samples, 864 tissue samples, and 366 follow-up blood samples. CONCLUSIONS: Prospective collection of biomaterials and associated clinical data has started in the Dutch Pancreas Biobank. Subsequent translational research will aim to improve treatment decisions based on disease characteristics.
OBJECTIVES: Large biobanks with uniform collection of biomaterials and associated clinical data are essential for translational research. The Netherlands has traditionally been well organized in multicenter clinical research on pancreatic diseases, including the nationwide multidisciplinary Dutch Pancreatic Cancer Group and Dutch Pancreatitis Study Group. To enable high-quality translational research on pancreatic and periampullary diseases, these groups established the Dutch Pancreas Biobank. METHODS: The Dutch Pancreas Biobank is part of the Parelsnoer Institute and involves all 8 Dutch university medical centers and 5 nonacademic hospitals. Adult patients undergoing pancreatic surgery (all indications) are eligible for inclusion. Preoperative blood samples, tumor tissue from resected specimens, pancreatic cyst fluid, and follow-up blood samples are collected. Clinical parameters are collected in conjunction with the mandatory Dutch Pancreatic Cancer Audit. RESULTS: Between January 2015 and May 2017, 488 patients were included in the first 5 participating centers: 4 university medical centers and 1 nonacademic hospital. Over 2500 samples were collected: 1308 preoperative blood samples, 864 tissue samples, and 366 follow-up blood samples. CONCLUSIONS: Prospective collection of biomaterials and associated clinical data has started in the Dutch Pancreas Biobank. Subsequent translational research will aim to improve treatment decisions based on disease characteristics.
Authors: T M Mackay; F J Smits; A E J Latenstein; A Bogte; B A Bonsing; H Bos; K Bosscha; L A A Brosens; L Hol; O R C Busch; G J Creemers; W L Curvers; M den Dulk; S van Dieren; L M J W van Driel; S Festen; E J M van Geenen; L G van der Geest; D J A de Groot; J W B de Groot; N Haj Mohammad; B C M Haberkorn; J T Haver; E van der Harst; G J M Hemmink; I H de Hingh; C Hoge; M Y V Homs; N C van Huijgevoort; M A J M Jacobs; E D Kerver; M S L Liem; M Los; H Lubbinge; S A C Luelmo; V E de Meijer; L Mekenkamp; I Q Molenaar; M G H van Oijen; G A Patijn; R Quispel; L B van Rijssen; T E H Römkens; H C van Santvoort; J M J Schreinemakers; H Schut; T Seerden; M W J Stommel; A J Ten Tije; N G Venneman; R C Verdonk; J Verheij; F G I van Vilsteren; J de Vos-Geelen; A Vulink; C Wientjes; F Wit; F J Wessels; B Zonderhuis; C H van Werkhoven; J E van Hooft; C H J van Eijck; J W Wilmink; H W M van Laarhoven; M G Besselink Journal: Trials Date: 2020-04-16 Impact factor: 2.279